HoliStick Medical SAS, a new portfolio company of French VC firm Truffle Capital, has secured global exclusive rights to a novel tissue repair technology created by researchers at Harvard University, MIT, Boston Children's Hospital, and Brigham & Women's Hospital.
The licensed technology is a specialized catheter device for minimally invasive repair of holes in heart or tissue defects in other organs. The catheter is designed to deploy soft structures,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?